癌症研究
体内
嵌合抗原受体
允许的
离体
细胞毒性T细胞
免疫系统
转染
黑色素瘤
免疫疗法
受体
细胞生物学
免疫检查点
化学
CD8型
抗原
肿瘤进展
内生
血管生成
癌症免疫疗法
渗透(HVAC)
结直肠癌
血管内皮生长因子A
激酶插入结构域受体
生物
血管内皮生长因子
转移
原发性肿瘤
抑制器
内皮干细胞
免疫学
肿瘤细胞
肿瘤坏死因子α
医学
肿瘤微环境
下调和上调
作者
Mengyao Li,Zefang Lu,Shijing Wang,Tianjiao Chu,Bozhao Li,Zhouliang Wu,Junsong Huang,程晋,Suying Wu,Jinna Ren,Fei Wu,Lifang Guo,Zhong Sheng Sun,Bo Zhu,Guangjun Nie,Yuming Fu,Suping Li
标识
DOI:10.1038/s41467-026-79342-7
摘要
T-cell therapies for solid tumors are restricted by abnormal tumor vasculature, which creates structural and immunological barriers to infiltration. Here we report a programmable mRNA lipid nanoparticle (LNP) platform that orchestrates a division-of-labor immune response in vivo. By modulating the LNP nano-bio interface through 10% 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) doping and indirect IgG-based anti-CD5 tethering, we achieve selective and efficient transfection of endogenous splenic T cells. This platform simultaneously generates two complementary chimeric antigen receptor (CAR)-T populations: a vascular endothelial growth factor receptor 2 (VEGFR2)-directed subset that transiently remodels the tumor endothelium, and a tumor-antigen-directed subset that executes cytotoxic clearance. Mechanistic analyses reveal that focal endothelial disruption creates a permissive window for the infiltration, expansion, and activation of tumor-directed CAR-T cells. In refractory melanoma and colorectal carcinoma models in female mice, this dual-programming strategy achieves superior tumor control and drives tumor regression while reducing systemic toxicity. By bypassing ex vivo manufacturing, this approach provides a scalable and host-directed strategy to breach infiltrative barriers in solid-tumor immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI